EF24 suppresses maturation and inflammatory response in dendritic cells

International Immunology

Volumn 24, Issue 7, 2012, Pages 455-464

  Vilekar, Prachi ^a   Awasthi, Shanjana ^a   Natarajan, Aravindan ^b   Anant, Shrikant ^b,c   Awasthi, Vibhudutta ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Curcumin; Dendritic cells; EF24; Inflammation; NF B

Indexed keywords

3,5 BIS(2 FLUOROBENZYLIDINE) 4 PYPERIDONE; ANTIINFLAMMATORY AGENT; B7 ANTIGEN; CD86 ANTIGEN; EF 24; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CONTROLLED STUDY; DENDRITE; GENETIC TRANSFECTION; INFLAMMATION; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZYLIDENE COMPOUNDS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELLS, CULTURED; CURCUMIN; CYTOKINES; DENDRITIC CELLS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NF-KAPPA B; PIPERIDONES; TRANSCRIPTIONAL ACTIVATION;

EID: 84864021447     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr121     Document Type: Article

References (40)

1. Nathan, C. 2002. Points of control in inflammation. Nature 420:846.
2. Rook, G. A. and Dalgleish, A. 2011. Infection, immunoregulation, and cancer. Immunol. Rev. 240:141.
3. Reis e Sousa, C. 2006. Dendritic cells in a mature age. Nat. Rev. Immunol. 6:476.
4. Baumgart, D. C., Thomas, S., Przesdzing, I. et al. 2009. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin. Exp. Immunol. 157:423.
5. Blanco, P., Palucka, A. K., Pascual, V. and Banchereau, J. 2008. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor. Rev. 19:41.
6. Lommatzsch, M., Bratke, K., Bier, A. et al. 2007. Airway dendritic cell phenotypes in inflammatory diseases of the human lung. Eur. Respir. J. 30:878.
7. Fujihara, M., Muroi, M., Tanamoto, K., Suzuki, T., Azuma, H. and Ikeda, H. 2003. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol. Ther. 100:171.
8. Takeda, K. and Akira, S. 2003. Toll receptors and pathogen resistance. Cell. Microbiol. 5:143.
9. De Smedt, T., Pajak, B., Klaus, G. G. et al. 1998. Antigen-specific T lymphocytes regulate lipopolysaccharide-induced apoptosis of dendritic cells in vivo. J. Immunol. 161:4476.
10. Flohe, S. B., Agrawal, H., Schmitz, D., Gertz, M., Flohe, S. and Schade, F. U. 2006. Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J. Leukoc. Biol. 79:473.
11. Kim, G. Y., Kim, K. H., Lee, S. H. et al. 2005. Curcumin inhibits immunostimulatory function of dendritic cells: mAPKs and translocation of NF-kappa B as potential targets. J. Immunol. 174:8116.
12. Shirley, S. A., Montpetit, A. J., Lockey, R. F. and Mohapatra, S. S. 2008. Curcumin prevents human dendritic cell response to immune stimulants. Biochem. Biophys. Res. Commun. 374:431.
13. Zhou, H., Beevers, C. S. and Huang, S. 2011. The targets of curcumin. Curr. Drug Targets 12:332.
14. Gradisar, H., Keber, M. M., Pristovsek, P. and Jerala, R. 2007. MD-2 as the target of curcumin in the inhibition of response to LPS. J. Leukoc. Biol. 82:968.
15. Youn, H. S., Saitoh, S. I., Miyake, K. and Hwang, D. H. 2006. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem. Pharmacol. 72:62.
16. Lagisetty, P., Vilekar, P., Sahoo, K., Anant, S. and Awasthi, V. 2010. CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis(benzylidene)-4-piperidones. Bioorg. Med. Chem. 18:6109.
17. Adams, B. K., Ferstl, E. M., Davis, M. C. et al. 2004. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg. Med. Chem. 12:3871.
18. Sun, D., Zhuang, X., Xiang, X. et al. 2010. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 18:1606.
19. Anand, P., Thomas, S. G., Kunnumakkara, A. B. et al. 2008. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem. Pharmacol. 76:1590.
20. Kasinski, A. L., Du, Y., Thomas, S. L. et al. 2008. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol. Pharmacol. 74:654.
21. Lagisetty, P., Powell, D. R. and Awasthi, V. 2009. Synthesis and structural determination of 3 3,5-bis(2-fluorobenzylidene)-4-piperidone analogs of curcumin. J. Mol. Str. 936:23.
22. Vilekar, P., Awasthi, V., Lagisetty, P., King, C., Shankar, N. and Awasthi, S. 2010. In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cellbased vaccine. BMC Immunol. 11:60.
23. Giacometti, A., Cirioni, O., Ghiselli, R. et al. 2004. Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am. J. Respir. Crit. Care Med. 169:187.
24. Awasthi, S. and Magee, D. M. 2004. Differences in expression of cell surface co-stimulatory molecules, Toll-like receptor genes and secretion of IL-12 by bone marrow-derived dendritic cells from susceptible and resistant mouse strains in response to Coccidioides posadasii. Cell. Immunol. 231:49.
25. Medzhitov, R., Preston-Hurlburt, P., Kopp, E. et al. 1998. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell. 2:253.
26. Awasthi, S. and Cox, R. A. 2003. Transfection of murine dendritic cell line (JAWS II) by a nonviral transfection reagent. Biotechniques 35:600, 604.
27. Brown, K. L., Cosseau, C., Gardy, J. L. and Hancock, R. E. 2007. Complexities of targeting innate immunity to treat infection. Trends Immunol. 28:260.
28. Adema, G. J. 2009. Dendritic cells from bench to bedside and back. Immunol. Lett. 122:128.
29. Mosley, C. A., Liotta, D. C. and Snyder, J. P. 2007. Highly active anticancer curcumin analogues. Adv. Exp. Med. Biol. 595:77.
30. Anand, P., Kunnumakkara, A. B., Newman, R. A. and Aggarwal, B. B. 2007. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4:807.
31. Carpenter, S. and O'Neill, L. A. 2009. Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem. J. 422:1.
32. Bottero, V., Withoff, S. and Verma, I. M. 2006. NF-kappaB and the regulation of hematopoiesis. Cell Death Differ. 13:785.
33. Jiang, W., Sun, R., Wei, H. and Tian, Z. 2005. Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages. Proc. Natl Acad. Sci. USA 102:17077.
34. Uronen-Hansson, H., Allen, J., Osman, M., Squires, G., Klein, N. and Callard, R. E. 2004. Toll-like receptor 2 (TLR2) and TLR4 are present inside human dendritic cells, associated with microtubules and the Golgi apparatus but are not detectable on the cell surface: integrity of microtubules is required for interleukin-12 production in response to internalized bacteria. Immunology 111:173.
35. Kluwe, J., Mencin, A. and Schwabe, R. F. 2009. Toll-like receptors, wound healing, and carcinogenesis. J. Mol. Med. 87:125.
36. Yoshimura, S., Bondeson, J., Foxwell, B. M., Brennan, F. M. and Feldmann, M. 2001. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, costimulatory molecules and cytokines. Int. Immunol. 13:675.
37. Hotchkiss, R. S. and Karl, I. E. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138.
38. Wang, E. L., Qian, Z. R., Nakasono, M. et al. 2010. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br. J. Cancer 102:908.
39. Jurenka, J. S. 2009. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern. Med. Rev. 14:141.
40. Hatcher, H., Planalp, R., Cho, J., Torti, F. M. and Torti, S. V. 2008. Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 65:1631.